Healthcare / Health Plans · Clinical Laboratory & Pathologyprovider
Digital Pathology Sign-Out
Readiness: Now — Deployable with established commercial tools today · Near-term — Proven but early — expect one to three years to mainstream · Emerging — Demonstrated, not yet production-mainstream
Readiness reflects an editorial assessment against a published rubric as of August 2026 — an observation about current tool maturity and adoption, not a prediction about specific products or timelines.
Trajectories describe the observable direction of human effort — not a prediction about specific roles, headcount, or individual careers.
What You Do Today
You sign out cases. The histology lab delivers the glass — H&E (hematoxylin and eosin) sections, recuts, deeper levels, immunohistochemistry — and you work each case at the scope: read against the requisition and the clinical history, compare to the gross description and any prior material, grade and stage, and enter the diagnosis in the LIS (laboratory information system). Some cases read in a single pass. Others need special stains, deeper levels, an outside consult, or a colleague at the multi-head scope. Frozen sections interrupt everything, because the surgeon is waiting with the patient open. Cancer resections go out as synoptic reports built on CAP (College of American Pathologists) cancer protocols, every required element filled. Turnaround time is tracked, the case does not leave until you sign it, and your name is on it.
AI Technologies
How It Works
The glass gets scanned. A slide scanner produces a whole-slide image, the image opens in a viewer alongside the case in the LIS (laboratory information system), and algorithms run against the pixels before you open it. Pre-screening models classify regions as suspicious or benign and mark the areas they want looked at first, so a large biopsy opens on a region of interest rather than on the corner of the section. Quantitative scoring models count what is otherwise counted by eye and estimated — nuclei, mitotic figures, percent and intensity of staining on immunohistochemistry — and return a number together with the area they measured, so the basis of the score can be inspected. Triage models read the pre-screen output and reorder the worklist, moving cases the algorithm calls suspicious ahead of cases it calls clean. Separately, image-quality checks catch scan failures — out-of-focus tiles, tissue missing from the scanned area, a slide loaded crooked — and route the slide for rescan before the case reaches you rather than after.
What Changes
Cases can be read wherever the images can be reached, subject to where the laboratory is licensed and accredited to report from, which changes how coverage is arranged and makes a second opinion a link rather than a courier run. Prior material sits beside current material on the same screen instead of being pulled from the file room. Specimen types where many parts come back negative can be ordered so the likely-positive cases are read first. Quantitative marker scores become more consistent between pathologists and between readings of the same slide, because the number comes from the image rather than from an estimate. Scan and quality problems surface before sign-out instead of during it. Regions flagged by the algorithm, and what you did with them, become part of a record that can be reviewed later.
What Stays the Same
You render the diagnosis and you sign the report. An algorithm that flags a region has not made a diagnosis — it has said where to look, and it can be confidently wrong on tissue, stains or preparations it was not trained on. Correlating the slide with the clinical history, the gross findings, prior biopsies and imaging stays human, and it is where discrepancies between the slide and the rest of the case surface. Deciding that a case needs immunohistochemistry, deeper levels, a molecular study or a colleague's eyes is a judgment about what that case needs, not a step in a workflow. Frozen section stays at the scope with the surgeon waiting. Validating an algorithm on your own scanner, your own stains and your own case mix before clinical use — and revalidating when any of those change — is a laboratory obligation under CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathologists) accreditation, not something a supplier can attest to on your behalf; a model that behaves one way on another laboratory's slides can behave differently on yours. Amending a report and telling a clinician the diagnosis has changed is a physician's conversation. The signature carries the liability.
Evidence & Sources
- •CLIA (Clinical Laboratory Improvement Amendments), administered by CMS
- •College of American Pathologists (CAP) Laboratory Accreditation Program checklists
- •CAP cancer protocols (synoptic reporting)
- •FDA device authorizations for whole-slide imaging systems and pathology software
- •ASCO/CAP biomarker testing guidelines
Sources listed are directional references, not formal citations. Verify against primary sources before using in business cases or presentations.
Last reviewed: August 2026
What To Do Next
This section won't tell you what your numbers should be. It will show you how to find them yourself. Every instruction below produces a real, verifiable result in your organization. No benchmarks, no projections — just the steps to build your own evidence.
Establish Your Baseline
Know where you are before you move
Before adopting AI tools for digital pathology sign-out, document your current state in utilization management.
Without a baseline, you can't tell whether AI actually improved digital pathology sign-out or just changed who does it.
Define Your Measures
What to track and how to calculate it
patient outcomes
How to calculate
Measure patient outcomes for digital pathology sign-out before and after AI adoption. Pull from your laboratory information system.
Why it matters
This is the most direct indicator of whether AI is adding value to utilization management.
clinical documentation quality
How to calculate
Track clinical documentation quality using the same methodology you use today. Don't change how you measure just because you changed how you work.
Why it matters
Speed without quality is just faster mistakes. Measure both together.
Start These Conversations
Who to talk to and what to ask
CMO or VP Clinical Operations
“What's our plan for AI in utilization management? Are we piloting, planning, or waiting?”
This tells you whether to experiment quietly or push for formal investment in digital pathology sign-out.
your laboratory information system administrator or vendor
“What AI capabilities exist in our current EHR system that we're not using? Most platforms are adding AI features faster than teams adopt them.”
The cheapest AI adoption is the features already included in your existing license.
a practitioner in utilization management at another organization
“Have you deployed AI for digital pathology sign-out? What worked, what didn't, and what would you do differently?”
Peer experience is more useful than vendor demos. Find someone who has actually done this.
Check Your Prerequisites
Confirm readiness before you invest
Check items as you confirm them.